IL105141A - Hydroxylated metabolites and derivatives of doxazosin as anti-atherosclerosis agents - Google Patents

Hydroxylated metabolites and derivatives of doxazosin as anti-atherosclerosis agents

Info

Publication number
IL105141A
IL105141A IL10514193A IL10514193A IL105141A IL 105141 A IL105141 A IL 105141A IL 10514193 A IL10514193 A IL 10514193A IL 10514193 A IL10514193 A IL 10514193A IL 105141 A IL105141 A IL 105141A
Authority
IL
Israel
Prior art keywords
medicament
compound
formula
doxazosin
atherosclerosis
Prior art date
Application number
IL10514193A
Other languages
English (en)
Other versions
IL105141A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL105141A0 publication Critical patent/IL105141A0/xx
Publication of IL105141A publication Critical patent/IL105141A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10W—GENERIC PACKAGES, INTERCONNECTIONS, CONNECTORS OR OTHER CONSTRUCTIONAL DETAILS OF DEVICES COVERED BY CLASS H10
    • H10W74/00—Encapsulations, e.g. protective coatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL10514193A 1992-04-01 1993-03-23 Hydroxylated metabolites and derivatives of doxazosin as anti-atherosclerosis agents IL105141A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86171492A 1992-04-01 1992-04-01

Publications (2)

Publication Number Publication Date
IL105141A0 IL105141A0 (en) 1993-07-08
IL105141A true IL105141A (en) 1998-10-30

Family

ID=25336560

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10514193A IL105141A (en) 1992-04-01 1993-03-23 Hydroxylated metabolites and derivatives of doxazosin as anti-atherosclerosis agents

Country Status (17)

Country Link
US (1) US5543411A (de)
EP (1) EP0564093B1 (de)
JP (1) JPH0624989A (de)
KR (1) KR0137927B1 (de)
AT (1) ATE187069T1 (de)
AU (1) AU660359B2 (de)
CA (1) CA2092983C (de)
DE (1) DE69327128T2 (de)
DK (1) DK0564093T3 (de)
ES (1) ES2139624T3 (de)
GR (1) GR3032373T3 (de)
HU (1) HU225113B1 (de)
IL (1) IL105141A (de)
MX (1) MX9301824A (de)
NZ (1) NZ247307A (de)
PT (1) PT564093E (de)
ZA (1) ZA932307B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
IL120303A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
IL120302A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
US20050165428A1 (en) * 2000-09-25 2005-07-28 Franco Kenneth L. Absorable surgical structure
EP1322234A2 (de) * 2000-09-25 2003-07-02 Cohesion Technologies, Inc. Resorbierbare anastomosestents sowie stopfen
WO2005007335A1 (ja) 2003-07-18 2005-01-27 Hamamatsu Photonics K.K. レーザ加工方法、レーザ加工装置、及び加工生産物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB271997A (en) * 1926-04-16 1927-06-09 Morris Engines Coventry Ltd Improvements relating to the driving of cam or other auxiliary shafts in internal combustion engines
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
GB8506174D0 (en) * 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
US4758569A (en) * 1987-08-26 1988-07-19 Pfizer Inc. Doxazosin as an anti-atherosclerosis agent

Also Published As

Publication number Publication date
CA2092983A1 (en) 1993-10-02
US5543411A (en) 1996-08-06
DE69327128D1 (de) 2000-01-05
GR3032373T3 (en) 2000-04-27
IL105141A0 (en) 1993-07-08
HU225113B1 (en) 2006-06-28
PT564093E (pt) 2000-04-28
KR930021203A (ko) 1993-11-22
HUT65849A (en) 1994-07-28
AU3562993A (en) 1993-10-07
ES2139624T3 (es) 2000-02-16
KR0137927B1 (ko) 1998-05-15
MX9301824A (es) 1994-02-28
DE69327128T2 (de) 2000-04-20
EP0564093B1 (de) 1999-12-01
NZ247307A (en) 1997-06-24
JPH0624989A (ja) 1994-02-01
EP0564093A1 (de) 1993-10-06
AU660359B2 (en) 1995-06-22
ZA932307B (en) 1994-09-30
HU9300947D0 (en) 1993-06-28
DK0564093T3 (da) 2000-03-27
ATE187069T1 (de) 1999-12-15
CA2092983C (en) 1996-12-31

Similar Documents

Publication Publication Date Title
CA1323572C (en) Doxazosin as an anti-atherosclerosis agent
US8343979B2 (en) Use of alkanoyl L-carnitine for the treatment of erectile dysfunction
Cutler Effect of antihypertensive agents on lipid metabolism
US5543411A (en) Hydroxylated metabolites and derivatives of doxazosin as anti-atherosclerosis agents
CA2060789C (en) Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides
EP0319288B1 (de) dl-5-[(2-Benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidin-2,4-dion als Antiatherosklerosemittel
AU705029B2 (en) Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide derivatives
US4582832A (en) Trimazosin as an anti-atherosclerosis agent
Mantero et al. Effect of atenolol and metoprolol on the anticoagulant activity of acenocoumarin.
JPH0573728B2 (de)

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees